Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG Does Not Predict Response to Endocrine Treatment in Hormone-Naïve, Node-Positive Prostate Cancer

European Urology

Volumn 57, Issue 5, 2010, Pages 830-835

  Boormans, Joost L ^a   Hermans, Karin G ^a   Made, Angelique C J Ziel van der ^a   van Leenders, Geert J H L ^a   Wildhagen, Mark F ^a   Collette, Laurence ^b   Schröder, Fritz H ^a   Trapman, Jan ^a   Verhagen, Paul C M S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Endocrine therapy; Prognosis; Prostate cancer; TMPRSS2 ERG

Indexed keywords

ANDROGEN; ANTIANDROGEN; COMPLEMENTARY DNA; GONADORELIN AGONIST; PORPHOBILINOGEN DEAMINASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; AVIAN ERYTHROBLASTOSIS ONCOVIRUS; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; ERG GENE; EXON; FUSION GENE; GENE EXPRESSION; GENE FUSION; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RNA ISOLATION; TMPRSS2 GENE; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 77949487521     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.08.013     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
3. Perner S., Mosquera J.-M., Demichelis F., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31 (2007) 882-888
4. Hermans K.G., van Marion R., van Dekken H., Jenster G., van Weerden W.M., and Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66 (2006) 10658-10663
5. Perner S., Demichelis F., Beroukhim R., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 (2006) 8337-8341
6. Sun C., Dobi A., Mohamed A., et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27 (2008) 5348-5353
7. Tomlins S.A., Laxman B., Varambally S., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 (2008) 177-188
8. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 23 (1992) 273-279
9. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nature Rev Cancer 7 (2008) 497-511
10. Huggins C., Stevens R.E., and Hodges C.V. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
11. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 (2007) 1596-1605
12. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
13. Schröder F.H., Kurth K.H., Fossa S.D., et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 172 (2004) 923-927
14. Dehm S.M., and Tindall D.J. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther 5 (2005) 63-74
15. Trapman J. Molecular mechanisms of prostate cancer. Eur J Cancer 37 (2001) S119-S125
16. Mostaghel E.A., and Nelson P.S. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22 (2008) 243-258
17. Mehra R., Tomlins S.A., Yu J., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68 (2008) 3584-3590
18. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: a possible mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 (1997) 314-319
19. Carver B.S., Tran J., Gopalan A., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41 (2009) 61924
20. King J.C., Xu J., Wongpivat J., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41 (2009) 524-526
21. Yoshimoto M., Joshua A.M., Cunha I.W., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favourable outcome. Mod Pathol 21 (2008) 1451-1460
22. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
23. Collette L., Burzykowski T., Carroll K.J., et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 23 (2005) 6139-6148
24. Han B., Mehra R., Dhanasekaran S.V., et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68 (2008) 7629-7637